Kingdom Investment Holdings

The usage of low dose Naltrexone for a variety of reasons is not new and it is not novel.  However, what is new is the ability to compound Naltrexone with SubMagna™ HMW, to enable delivery in a sublingual (under the tongue) dosage form that can also be swallowed.  To learn more about this SubMagna™ HMW base, review the information found at www.submagna.com.

Patients that are prescribed a compounded version of Naltrexone often have a dosage of anywhere from 0.5mg to 5mg daily.  The challenge when this compounded medication is delivered via a compounded capsule, or a compounded troche is apparent – to change a patient’s dosage typically requires a new compounded version to be prepared.  This is time-consuming and can be costly as many frequent changes in dosage may need to occur until a stable dose is attained.

By compounding with SubMagna™ HMW as the base, a patient can have his/her dosage changed without ever having to go back to the pharmacy to obtain a different strength. The volume of the dose taken can simply be increased or decreased, when necessary, as prescribed. This is fundamentally easier for the patient, for the prescriber and for the pharmacy.

If you’re looking for a compounding base to deliver Naltrexone that can be absorbed through the mucosal tissue in the oral cavity, or in the stomach, that enables a change in dosage without the necessity of making a new compound, look no further than SubMagna™ HMW.